EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

HLA-B*58:01 screening in Asia-Pacific is an ethical imperative – not just a cost question

Wei Leik Ng, Emily Tsui Yee Tse, Prawira Oka, Hooi Min Lim, Sky Wei Chee Koh, Rizawati Ramli, Hung Chiun Lau, Benjamin Chih Chiang Lam, Laurie J Goldsmith, Adina Abdullah, Lay Hoon Goh

Journal of Global Health · 2025

DOI: 10.7189/jogh.15.03037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Global Health, 2025. Verfasst von Wei Leik Ng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: HLA-B Antigens, Allopurinol, Genetic Testing, Mass Screening. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allopurinol remains the first-line treatment for gout; however, it carries a risk of severe cutaneous adverse reactions (SCARs), particularly among carriers of the HLA-B*58:01 allele. In the Asia-Pacific region, screening practices vary widely due to infrastructure gaps, cost concerns, and differing health policies. For example, while cost-effectiveness analyses have influenced screening decisions in some countries, they often overlook long-term health system burdens and ethical imperatives. Therefore, screenings should not be withheld solely on economic grounds, especially when they can prevent life-threatening outcomes. For that reason, a targeted, risk-based approach that integrates genetic and clinical factors could offer a practical and equitable path forward, improving pharmacogenomic literacy, expanding access to testing, developing regional data-sharing platforms, and involving patients in co-designing screening strategies. Rapid point-of-care testing and integration of screening process with existing care pathway may further support this implementation. However, a coordinated regional effort is needed to ensure safer prescribing and equitable access to pharmacogenomic screening across diverse healthcare settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-B AntigensAllopurinolGenetic TestingMass ScreeningHumansCost-Benefit AnalysisAsia

Substanzen

HLA-B AntigensAllopurinolHLA-B*58:01 antigen

Autor:innen und Institutionen

  • Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • SingHealth Polyclinics, Singapore, Singapore.
  • SingHealth-Duke NUS Family Medicine Academic Clinical Program, Singapore, Singapore.
  • National University Polyclinics, National University Health System, Singapore, Singapore.
  • Division of Family Medicine, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Zitieren

APA

Ng, W. L., Tse, E. T. Y., Oka, P., Lim, H. M., Koh, S. W. C., Ramli, R., Lau, H. C., Lam, B. C. C., Goldsmith, L. J., Abdullah, A., & Goh, L. H. (2025). HLA-B*58:01 screening in Asia-Pacific is an ethical imperative – not just a cost question. Journal of Global Health. https://doi.org/10.7189/jogh.15.03037

Vancouver

Ng WL, Tse ETY, Oka P, Lim HM, Koh SWC, Ramli R, et al. HLA-B*58:01 screening in Asia-Pacific is an ethical imperative – not just a cost question. Journal of Global Health. 2025. doi:10.7189/jogh.15.03037

BibTeX
@article{Ng2025,
  author = {Ng, Wei Leik and Tse, Emily Tsui Yee and Oka, Prawira and Lim, Hooi Min and Koh, Sky Wei Chee and Ramli, Rizawati and Lau, Hung Chiun and Lam, Benjamin Chih Chiang and Goldsmith, Laurie J and Abdullah, Adina and Goh, Lay Hoon},
  title = {HLA-B*58:01 screening in Asia-Pacific is an ethical imperative – not just a cost question},
  journal = {Journal of Global Health},
  year = {2025},
  doi = {10.7189/jogh.15.03037}
}
Kostenlos starten →